Immuno-Oncology Hong Kong 2016 is the 21st Annual Scientific Symposium of the Hong Kong Cancer Institute.
The symposium is co-organized by the Department of Clinical Oncology and the Hong Kong Cancer Institute in conjunction with Partner State Key Laboratory of Oncology in South China at the Chinese University of Hong Kong.
Cancer treatment is fast changing. With advent of molecular targeted therapy and immuno--oncology, we will be able to transform advanced stage cancer into a chronic illness. “Immuno-Oncology Hong Kong 2016” aims at providing an international platform for all clinical and preclinical, scientists, academia, healthcare professionals and pharmaceutical companies to share and discuss cancer immunotherapeutic strategies in Asia.
The two-day regional meeting focuses on topics including basic biology, early drug development, biomarkers and site-specific applications and challenges in lung cancer, nasopharyngeal cancer, head & neck cancer, sarcoma/melanoma, genitourinary cancer, haematological, gastrointestinal & hepatocellular cancers. Pioneer leaders from Asia, Europe, Japan and United States will gather in Hong Kong to share their insightful experience and future prospective.
Come along to ecancer's satellite symposium...
"Designing the optimal treatment pathway for gastric cancer patients: current applications and future perspectives"
12:50 – 14:00, Sunday 20 November, Aberdeen Room
Hear from the following leading experts:
-
Prof Yung-Jue Bang, Department of Internal Medicine, Seoul National University College of Medicine, South Korea
-
Prof Florian Lordick, University Cancer Centre Leipzig, University Medicine Leipzig, Germany
-
Prof Gordon McVie, Kings College London, UK and The FIRC Institute of Molecular Oncology (IFOM), Milan, Italy
-
Prof Daisuke Sakai, Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Japan
